Delafloxacin Meglumine Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as MELINTA. It is marketed under 1 brand name, including BAXDELA. Available in 2 different strengths, such as EQ 300MG BASE/VIAL, EQ 450MG BASE, and administered through 2 routes including POWDER;INTRAVENOUS, TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"40747","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US9539250B2","cleaned_patent_number":"9539250","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-10-07","publication_date":"2017-01-10","legal_status":"Granted"} US9539250B2 Molecular Formulation 10 Jan, 2017 Granted 07 Oct, 2025
{"application_id":"40746","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US8969569B2","cleaned_patent_number":"8969569","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-10-07","publication_date":"2015-03-03","legal_status":"Granted"} US8969569B2 Formulation 03 Mar, 2015 Granted 07 Oct, 2025
{"application_id":"40745","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US8648093B2","cleaned_patent_number":"8648093","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-10-07","publication_date":"2014-02-11","legal_status":"Granted"} US8648093B2 Formulation 11 Feb, 2014 Granted 07 Oct, 2025
{"application_id":"40744","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US8273892B2","cleaned_patent_number":"8273892","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-08-06","publication_date":"2012-09-25","legal_status":"Patented case"} US8273892B2 Molecular 25 Sep, 2012 Patented case 06 Aug, 2026
{"application_id":"40729","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US8252813B2","cleaned_patent_number":"8252813","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-10-02","publication_date":"2012-08-28","legal_status":"Granted"} US8252813B2 Formulation 28 Aug, 2012 Granted 02 Oct, 2026
{"application_id":"40776","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"3ecf95748df94158a713","publication_number":"US9200088B2","cleaned_patent_number":"9200088","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2015-12-01","legal_status":"Granted"} US9200088B2 Formulation 01 Dec, 2015 Granted 13 Mar, 2029
{"application_id":"2455","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"3ecf95748df94158a713","publication_number":"US8410077B2","cleaned_patent_number":"8410077","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2013-04-02","legal_status":"Granted"} US8410077B2 Formulation 02 Apr, 2013 Granted 13 Mar, 2029
{"application_id":"40775","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"3ecf95748df94158a713","publication_number":"US7635773B2","cleaned_patent_number":"7635773","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2009-12-22","legal_status":"Granted"} US7635773B2 Formulation 22 Dec, 2009 Granted 13 Mar, 2029
{"application_id":"40752","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"3ecf95748df94158a713","publication_number":"US9750822B2","cleaned_patent_number":"9750822","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2017-09-05","legal_status":"Granted"} US9750822B2 Formulation 05 Sep, 2017 Granted 13 Mar, 2029
{"application_id":"40781","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"852b283da0764a33a073","publication_number":"US8871938B2","cleaned_patent_number":"8871938","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-09-23","publication_date":"2014-10-28","legal_status":"Granted"} US8871938B2 Molecular 28 Oct, 2014 Granted 23 Sep, 2029
{"application_id":"55728","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"ca27c40788754bf98ed5","publication_number":"US8466174B2","cleaned_patent_number":"RE46617","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-12-28","publication_date":"2013-06-18","legal_status":"Granted"} USRE46617E1 Molecular 18 Jun, 2013 Granted 28 Dec, 2029
{"application_id":"40743","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"194e090aed3445cf80bc","publication_number":"US7728143B2","cleaned_patent_number":"7728143","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-06-19","publication_date":"2010-06-01","legal_status":"Granted"} US7728143B2 Molecular 01 Jun, 2010 Granted 19 Jun, 2031
{"application_id":"138482","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"","publication_number":"","cleaned_patent_number":"12138257","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-05-01","publication_date":"2024-11-12","legal_status":"Patented Case"} US12138257B2 Formulation 12 Nov, 2024 Patented Case 01 May, 2032
{"application_id":"34843","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"63f22001fd064021a5c0","publication_number":"US9493582B2","cleaned_patent_number":"9493582","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-02-27","publication_date":"2016-11-15","legal_status":"Granted"} US9493582B2 Formulation 15 Nov, 2016 Granted 27 Feb, 2033
{"application_id":"124162","ingredient":"DELAFLOXACIN MEGLUMINE","trade_name":"BAXDELA","family_id":"","publication_number":"US12036219B2","cleaned_patent_number":"12036219","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-06-02","publication_date":"2024-07-16","legal_status":"Granted"} US12036219B2 16 Jul, 2024 Granted 02 Jun, 2034

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Delafloxacin Meglumine

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.